GlassScriptPhysician profile
Mohammad Qasaymeh
NPI 1528074341
$42,412.15
in general payments reported to CMS, 2019-2025
64 companies · $2,146 in 2025
The $2,146 reported for 2025 was more than what 79% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,064 · 2020: $1,894 · 2021: $25K · 2022: $5,048 · 2023: $2,702 · 2024: $2,386 · 2025: $2,146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,091 · Education: $143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,091.14 |
| Education | $142.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $21,282.28 | 2020-2021 | |
| Abbvie INC. | $5,482.44 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $2,810.07 | 2022 | |
| Livanova USA, INC. | $2,534.14 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Ucb, INC. | $1,896.26 | 2019-2025 | Nayzilam, Fintepla, Briviact |
| Sk Life Science, INC. | $793.46 | 2021-2025 | Xcopri |
| Teva Pharmaceuticals USA, INC. | $760.95 | 2019-2024 | Ajovy, Austedo |
| Pfizer INC. | $734.26 | 2023-2025 | |
| Jazz Pharmaceuticals INC. | $576.11 | 2022-2025 | |
| Allergan, INC. | $509.07 | 2019-2022 | |
| Neurelis, INC. | $465.36 | 2020-2025 | Valtoco |
| Greenwich Biosciences, INC. | $377.21 | 2019-2021 | |
| Amgen INC. | $326.05 | 2019-2023 | Aimovig |
| Ge Healthcare | $323.45 | 2019-2024 | |
| Biogen, INC. | $312.80 | 2019-2024 | Spinraza |
Show all 63 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,439,969.01 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Qasaymeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.